CRISPR Therapeutics AG: general counsel and secretary Kasinger James R. sold 1,040 shares

What happened Kasinger James R., general counsel and secretary, exercised or converted 2,113 restricted stock units into 2,113 shares on Oct 13, 2026 (derivative transaction) and sold 1,040 shares in an open market sale on Oct 14, 2026 at $49.26 per share for $51,230. The Form 4 was filed on Oct 15, 2026.

Key details

• Transaction dates and prices: Oct 13, 2026 — exercised/converted 2,113 restricted stock units (derivative; no price reported); Oct 14, 2026 — open market sale of 1,040 shares at $49.26, total $51,230.
• Shares owned after the transaction: the filing does not report total shares owned after the transactions.
• Relevant footnotes from the filing:
  • F1: Each restricted stock unit represents a contingent right to receive one share of CRSP common shares.
  • F2: The 1,040 shares sold represent the number required to be sold to cover tax withholding in connection with the vesting; the sale was mandated by the company’s RSU settlement policy and is not a discretionary trade by the reporting person.
  • F3: The restricted stock unit award was granted on Oct 13, 2023 for 6,340 common shares, with one third vesting on Oct 13, 2024, one third on Oct 13, 2025, and one third on Oct 13, 2026.
• Filing date: Oct 15, 2026.

Why it may matter

• The filing shows an exercise/conversion of restricted stock units followed by an open market sale to cover tax withholding (a required sale under company policy), not a discretionary sale.
• The derivative entries on Oct 13, 2026 indicate conversion of contingent awards into shares; 1,040 of those shares were sold on Oct 14, 2026. This filing does not show why the insider traded or why the company acted.